Welcome to our dedicated page for Intercure Ltd. news (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure Ltd. stock.
Intercure Ltd (INCR) delivers pharmaceutical-grade medical cannabis through its vertically integrated operations, maintaining GMP certification across production facilities. This news hub provides investors and healthcare professionals with essential updates on regulatory developments, research advancements, and strategic partnerships.
Access timely announcements about cultivation innovations, international distribution expansions, and compliance milestones. Our curated collection features earnings reports, product approvals, and biomed research breakthroughs that shape the medical cannabis sector.
Key updates include manufacturing process enhancements, new market entries, and collaborations with healthcare institutions. Bookmark this page for structured access to operational developments and quality assurance initiatives that maintain Intercure's position as a global cannabis industry leader.
On April 24, 2023, InterCure Ltd (NASDAQ: INCR) announced a lawsuit filed by minority shareholders of its subsidiary, Cannolam, in Tel Aviv-Jaffa District Court. This legal action arises from disagreements regarding Cannolam's management. InterCure has conducted a preliminary review of the claims and believes they lack legal merit. The company is exploring legal options, including potential counterclaims, to protect its interests. Established as the leading medical cannabis company outside North America, InterCure operates through its subsidiary Canndoc, which is Israel’s largest licensed cannabis producer, known for its GMP-certified products.
InterCure, a leading global cannabis company, has signed a collaboration agreement with TYSON 2.0, the premium cannabis brand founded by boxing legend Mike Tyson. The agreement provides InterCure with an exclusive distribution license to cultivate, manufacture, sell, and distribute TYSON 2.0 products in various key international markets, including Israel, Australia, the UK, Germany, and Switzerland.
This strategic partnership aims to expand InterCure's presence in rapidly growing legal cannabis markets. According to EuroMonitor International, the Israeli and German cannabis markets are projected to reach sales of $3.4 billion and $3 billion by 2027, respectively. The partnership will also allow InterCure to use TYSON 2.0's intellectual property and genetics for production. The agreement's terms are subject to change as a definitive agreement is finalized.
